This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

A Potent Analogue of the Kidney Hormone, 1,25-Dihydroxycholecalciferol

James C. M. Chan, MD; Susan B. Oldham, PhD; Michael F. Holick, PhD; Hector F. DeLuca, PhD

JAMA. 1975;234(1):47-52.

Abstract
In chronic renal disease, the synthesis of the kidney hormone, 1,25-dihydroxyvitamin D₃ (1,25-[OH]₂D₃), is impaired, thus contributing to the development of renal osteodystrophy. The clinical use of 1,25-[OH]₂D₃ is limited, due to the complexity and expense of its chemical synthesis.

This study reports the use of 1--hydroxyvitamin D₃ (1--OH-D₃), an active analogue of (1,25-[OH]₂D₃, in eight patients with chronic renal failure, five of whom were undergoing long-term hemodialysis. The drug was given orally for 6 to 260 days at a dosage of 1µg to 4µg/day. Short-term (21 days) balance studies showed an increase in intestinal calcium absorption and a simultaneous fall in serum parathyroid hormone levels during administration of 1--OH-D₃. In two long-term studies (160 and 260 days), roentgenographic improvement of renal osteodystrophy was seen after 45 and 185 days, respectively.

The data indicate that 1--OH-D₃ holds considerable promise for the prevention and treatment of renal osteodystrophy.

(JAMA 234:47-52, 1975)

Author Affiliations
From the Department of Nephrology, Children's Hospital National Medical Center, and the Department of Child Health and Development, George Washington University School of Medicine, Washington, DC (Dr. Chan); the Children's Hospital of Los Angeles, and the Department of Medicine and Pediatrics, University of Southern California School of Medicine, Los Angeles (Drs. Chan and Oldham); and the Department of Biochemistry, College of Agricultural and Life Sciences, University of Wisconsin, Madison (Drs. Holick and DeLuca).

Footnotes
Read in part before the 44th annual meeting of the Society for Pediatric Research, Washington, DC, May 3, 1974; the Third International Symposium of Pediatric Nephrology, Washington, DC, Oct 1, 1974; and the 14th International Congress of Pediatrics, Buenos Aires, Oct 5, 1974.

Reprint requests to Department of Nephrology, Children's Hospital National Medical Center, 2125 Thirteenth St NW, Washington, DC 20009 (Dr. Chan).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Effects of Calciferol and Its Metabolites on Patients With Chronic Renal Failure: II. Calcitriol, 1{alpha}-Hydroxyvitamin D3, and 24,25-Dihydroxyvitamin D3
Voigts et al.
Arch Intern Med 1983;143:1205-1211.
ABSTRACT  

Calcium and Parathyroid Disorders in Children: Chronic Renal Failure and Treatment With Calcitriol
Chan and DeLuca
JAMA 1979;241:1242-1244.
ABSTRACT  

1,25 Dihydroxycholecalciferol Effects in Chronic Dialysis: A Double-Blind Controlled Study
BERL et al.
ANN INTERN MED 1978;88:774-780.
ABSTRACT  

A Model For Clinical Research Studies of Renal Osteodystrophy in Children
Norman et al.
Arch Intern Med 1978;138:866-868.
ABSTRACT  

Growth Velocity in a Child on Prolonged Hemodialysis: Beneficial Effect of 1-{alpha}-Hydroxyvitamin D3
Chan and DeLuca
JAMA 1977;238:2053-2054.
ABSTRACT  

End-Stage Kidney Failure in Children: A Brief Commentary on Hemodialysis and Transplantation
Chan
CLIN PEDIATR 1976;15:991-995.
 

Renal Osteodystrophy in Children: Progress in Its Management
Chan
CLIN PEDIATR 1976;15:996-1002.